1. Home
  2. VTRS vs KGC Comparison

VTRS vs KGC Comparison

Compare VTRS & KGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VTRS
  • KGC
  • Stock Information
  • Founded
  • VTRS 1961
  • KGC 1993
  • Country
  • VTRS United States
  • KGC Canada
  • Employees
  • VTRS N/A
  • KGC N/A
  • Industry
  • VTRS Medicinal Chemicals and Botanical Products
  • KGC Precious Metals
  • Sector
  • VTRS Health Care
  • KGC Basic Materials
  • Exchange
  • VTRS Nasdaq
  • KGC Nasdaq
  • Market Cap
  • VTRS 11.0B
  • KGC 12.0B
  • IPO Year
  • VTRS N/A
  • KGC N/A
  • Fundamental
  • Price
  • VTRS $8.98
  • KGC $11.40
  • Analyst Decision
  • VTRS Hold
  • KGC Buy
  • Analyst Count
  • VTRS 4
  • KGC 3
  • Target Price
  • VTRS $10.50
  • KGC $11.00
  • AVG Volume (30 Days)
  • VTRS 15.7M
  • KGC 24.3M
  • Earning Date
  • VTRS 02-27-2025
  • KGC 05-06-2025
  • Dividend Yield
  • VTRS 5.35%
  • KGC 1.05%
  • EPS Growth
  • VTRS N/A
  • KGC 126.95
  • EPS
  • VTRS N/A
  • KGC 0.77
  • Revenue
  • VTRS $14,739,300,000.00
  • KGC $5,148,800,000.00
  • Revenue This Year
  • VTRS N/A
  • KGC $9.91
  • Revenue Next Year
  • VTRS $0.99
  • KGC N/A
  • P/E Ratio
  • VTRS N/A
  • KGC $14.80
  • Revenue Growth
  • VTRS N/A
  • KGC 21.44
  • 52 Week Low
  • VTRS $8.77
  • KGC $5.44
  • 52 Week High
  • VTRS $13.55
  • KGC $12.29
  • Technical
  • Relative Strength Index (RSI)
  • VTRS 25.27
  • KGC 54.70
  • Support Level
  • VTRS $9.25
  • KGC $10.42
  • Resistance Level
  • VTRS $9.74
  • KGC $11.28
  • Average True Range (ATR)
  • VTRS 0.38
  • KGC 0.47
  • MACD
  • VTRS -0.07
  • KGC -0.00
  • Stochastic Oscillator
  • VTRS 7.61
  • KGC 83.33

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

About KGC Kinross Gold Corporation

Kinross Gold is a Canada-based gold producer, producing roughly 2.2 million gold equivalent ounces in 2023. The company had about a decade of gold reserves at the end of 2023. It operates mines in the Americas and West Africa after selling its low-cost Russian operations in 2022 in response to the invasion of Ukraine. The company has historically used acquisitions to fuel expansion into new regions and production growth. In 2022, Kinross purchased the Great Bear project in Canada, which, if developed, could produce an average of more than 500,000 ounces of gold per year for at least a decade.

Share on Social Networks: